After multiple failed procedures at other medical institutions, Colorado man successfully treated for Atrial Fibrillation at Texas Cardiac Arrhythmia Institute at St. David#s Medical Center

Food and Healthcare Press Releases Wednesday February 14, 2018 14:08
AUSTIN, Texas--14 Feb--PRNewswire/InfoQuest
Five years ago, Ryan Wiseman was in the prime of his life.
"I was thinking I was on top of the world," Wiseman said. "I was keeping myself in shape. I was taking care of myself mentally and physically. My relationship was solid."
Then, during a routine medical exam while serving in the military in California, doctors discovered he had Atrial Fibrillation, or A Fib.

"Atrial fibrillation is a rhythm disorder of the upper chambers of the heart during which the upper chambers lose the mechanical function, so they don't contract," Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., executive medical director of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center , said.

"Suddenly everything changes, and I'm not able to work out anymore. I may not live as long as I expected," Wiseman said. "These were all emotional shocks for my wife and me to learn."
In just five years, Wiseman underwent 10 cardioversions, four ablations and one failed surgery to treat his A Fib, but all were unsuccessful.

"After my third ablation, the cardiologist that I have out in Denver, they looked into alternatives to where I could go across the country and they were saying, 'We've done the best we can. We don't want to take any more risks than we feel comfortable taking. We're going to send you to the best guy that we have in the country,'" Wiseman said. "So they sent me to Dr. Natale."

"The typical age of a person with A Fib is about late 50s, early 60s, so Ryan is clearly an exception, but this is a genetic disease," Dr. Natale said. "Unfortunately, because the upper chamber is not contracting, A Fib can increase the risk of stroke and heart failure."

A Fib is the most common cardiac arrhythmia, affecting millions of Americans. A Fib can cause blood to pool and form clots in the left atrial appendage (LAA). If a blood clot breaks loose, it can travel to the brain, causing a stroke.

Approximately 20 percent of all strokes occur in patients with A Fib, and A Fib-related strokes are more frequently fatal and disabling. The most common treatment to reduce the risk of stroke in patients with A Fib is the use of blood-thinning warfarin medication. Despite its proven efficacy, long-term warfarin medication is not well-tolerated by some patients, and it carries a significant risk for bleeding complications.

As a result, doctors decided to close Wiseman's LAA mechanically using the WATCHMAN Left Atrial Appendage Closure (LAAC) Device .

The WATCHMAN Implant is a permanent implant designed to close the LAA to keep harmful blood clots from the LAA from entering the blood stream. By closing off the LAA, the risk of stroke may be reduced, and over time, patients may be able to stop taking warfarin.

"Imagine an umbrella that springs out and closes it," Dr. Natale said.

"To eliminate my stroke risk and not have to be on blood thinners anymore—that's huge for me," Wiseman said. "Being able to go back to running and not having to worry about falling down or somebody hitting me in the chest. I make jokes about it with friends, 'Hey don't hit me in the chest. I'm on blood thinners, I might die.' To a certain degree, it's kind of funny, but also at the same time it's a real life-threatening risk that if I fall down some stairs, I may not get back up."

"This is true for any patient, not just Ryan, but for him it's more important because he's a young parent, so he has to take care of young kids— and at the same time, he has to make sure he can financially provide for his family," Dr. Natale said. "So it's actually very important."

Now, at 32 years of age, Wiseman has bounced back.

"I feel really great, which is an awesome place to be," Wiseman said. "When you have atrial fibrillation, your heart isn't pumping as efficiently and, in general, you feel bad. And in general, I feel good—which is awesome."

The WATCHMAN was approved by the U.S. Food and Drug Administration in March 2015. TCAI was involved in clinical trials to study its effectiveness in the United States for nearly a decade, and it was the first facility in Texas to implant the WATCHMAN device in a patient with non-valvular A Fib in 2015.

Media Contact:
Erin Ochoa
Elizabeth Christian Public Relations
512-472-9599

Latest Press Release

Accor Pattaya Blood Donation #3/2019

On Tuesday 17th, September 2019, Hotel Baraquda Pattaya - MGallery and Mercure Pattaya Hotel attended to Accor Pattaya Blood Donation #3/2019 at Veranda Resort Pattaya Na Jomtien - MGallery, MM Meeting Room. The event started at 10.00 a.m. to 02.00 p.m....

Tresiba(R) Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

According to new data from the CONCLUDE head-to-head trial, Tresiba(R) (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in...

BookDoc, partners it#s way to being Southeast Asia#s Next Generation Healthcare Ecosystem is looking to raise Series A from Strategic partners

This year crosses 100 strategic partnerships in over 20 cities across Malaysia, Singapore, Indonesia, Thailand and Hong Kong. Since commenced operations in 2015, BookDoc has grown exponentially with four consecutive years of over 450% annual growth rate...

United Nations Political Declaration on Universal Health Coverage Finally has Some Teeth

FDI World Dental Federation (FDI) welcomes the long overdue commitment to strengthening oral health in the UN Political Declaration on Universal Health Coverage (UHC). The declaration will be officially adopted by world leaders at the UN High-Level...

Ozempic(R) Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza(R) and Canagliflozin in People With Type 2 Diabetes

Novo Nordisk announced today the results from two Ozempic(R) (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic(R) was superior to treatment with the SGLT-2 inhibitor canagliflozin...

Related Topics